ThinkstockAmgen Inc. (NASDAQ: AMGN) released its third quarter earnings report Wednesday after the markets closed. The biotech giant had $2.72 in earnings per share (EPS) on $5.72 billion in revenue compared to consensus estimates…
Amgen is scheduled to report its third-quarter financial results after the markets close on Wednesday.
With specialty pharmaceutical stocks having the chance to move dramatically higher, three large cap leaders are RBC's favorites now.
Boston Scientific reported better-than-expected third-quarter financial results before the markets opened on Wednesday.
Gilead Sciences reported its third-quarter financial results after the markets closed on Tuesday.
Gilead Sciences is set to report its third-quarter financial results after the markets close on Thursday.
HCA is out with earnings, but there is a serious question here when it comes to the greater good: should it, or other hospitals, be buying back stock?
Pfizer and Merck both released their third-quarter earnings on Tuesday morning. So, which drug giant is looking better after earnings?
The October 15 short interest data have been compared with the previous figures, and for most of the selected pharmaceutical stocks, short interest was mixed.
The October 15 short interest data have been compared with the previous figures, and short interest mixed in these selected biotech stocks.
Pfizer is scheduled to release its third-quarter financial results before the markets open on Tuesday.
Merckis expected to report its third-quarter financial results before the markets open on Tuesday.
Endo International and BioDelivery Sciences have announced that the U.S. Food and Drug Administration (FDA) approved their long-term opioid treatment, Belbuca.
These biotech stocks 24/7 Wall St. has picked stood out from the rest with at least 25% gains over the course of the past week.
ThinkstockJanssen Biotech announced that the U.S. Food and Drug Administration (FDA) approved Yondelis (trabectedin) for the treatment of patients with unresectable or metastatic liposarcoma (LPS) or leiomyosarcoma (LMS) who received a prior anthracycline-containing regimen.…